# Impact of Initiating Tiotropium Alone Versus Initiating Tiotropium in Combination With Fluticasone Propionate/Salmeterol Xinafoate Combination (FSC) on Chronic Obstructive Pulmonary Disease-related Outcomes in Patients With Pre-existing Exacerbations

> **NCT01381406** · — · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 3333 (actual)

## Conditions studied

- Pulmonary Disease, Chronic Obstructive

## Interventions

- **DRUG:** TIO
- **DRUG:** TIO+FSC

## Key facts

- **NCT ID:** NCT01381406
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2008-07
- **Primary completion:** 2010-06
- **Final completion:** 2010-09
- **Target enrollment:** 3333 (ACTUAL)
- **Last updated:** 2017-06-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01381406

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01381406, "Impact of Initiating Tiotropium Alone Versus Initiating Tiotropium in Combination With Fluticasone Propionate/Salmeterol Xinafoate Combination (FSC) on Chronic Obstructive Pulmonary Disease-related Outcomes in Patients With Pre-existing Exacerbations". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01381406. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*